Bayer Pharma Aktiengesellschaft

Bayer Intellectual Property Gmbh

Bayer Aktiengesellschaft

Bayer Schering Pharma Ag

Bayer Healthcare Aktiengesellschaft

Susanne Röhrig

Karl-Heinz Schlemmer

Stefan Heitmeier

Adrian Tersteegen

Christoph Gerdes

Alexander Hillisch

Anja Buchmüller

Martina Victoria Schmidt

Mark Jean Gnoth

Henrik Teller

Elisabeth Perzborn

Martina Schäfer

Ulrich Rester

Tom Kinzel

Alexander Straub

Thomas Lampe

Yolanda Cancho Grande

Jens Pohlmann

Dirk Heimbach

Michael Sperzel

Kersten Matthias Gericke

Eloisa Jimenez Nunez

Katja Zimmermann

Mario Jeske

Hartmut Schirok

Jürgen Klar

Michael Gerisch

Eckhard Bender

Joachim Schuhmacher

Johannes Köbberling

Andreas Wilmen

Dmitry Zubov

Nils Burkhardt

Niels Svenstrup

Christian Stegmann

Stephan Siegel

Manuel Ellermann

Maria Köllnberger

Julia Straβburger

Georges Von Degenfeld

Karen Engel

Metin Akbaba

Julia Strassburger

Matthias Werner

Jan Stampfuß

Kristin Beyer

Swen Allerheiligen

Joseph Pernerstorfer

Jorma Haßfeld

Josef Pernerstorfer

Jens Ackerstaff

Marcus Bauser

Dirk Schneider

Mark Meininghaus

Elke Dittrich-Wengenroth

Yolanda Cancho-Grande

Jochen Strayle

Philip Lienau

Dieter Lang

Bernd Riedl

Daniel Meibom

Mario Lobell

Holger Paulsen

Joachim Krüger

Jorma Haβfeld

Sabine Arndt

Jorma Hassfeld

Christian R Thomas

Julia Straßburger

Uwe Saatman

Jan Stampfuss

Uwe Saatmann

Pascal Ellerbrock

Katharina Meier

Georges Degenfeld

Josef Pernerstofer

Stephan Jordan

Eloisa Jimènez Nùnez

Gaelle Valot

Imke Meyer

Jörg Heiermann

Willem Jan Hengeveld

Eloisa Jiménez Núnez

Eloisa Jimenez Núnez

Eloisa Jimenez-Nunez

Jochen Stayle

Dimitry Zubov

The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

(Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

Substituted oxopyridine derivatives

The invention relates to substituted oxopyridine derivatives of formula (I) and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders. 

Substituted oxopyridine derivatives and use thereof cardiovascular disorders

The invention relates to substituted oxopyridine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

The invention relates to substituted pyridobenzazepine and pyridobenzazocine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives

The present application relates to novel substituted piperidinylpyrazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired hemostatic disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of heavy menstrual bleeding, postpartum hemorrhage, hemorrhagic shock, hemorrhagic cystitis, gastrointestinal hemorrhage, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

Piperidinylpyrazolopyrimidinones and their use

Substituted oxopyridine derivatives and use thereof as factor XIa/plasma

Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders

The invention relates to substituted benzoxazoles and to processes for their preparation and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of cardiovascular disorders, preferably of thrombotic or thromboembolic disorders.

Substituted benzoxazoles

Growing community of inventors

Hilden, Germany

Susanne Röhrig